ClarVista HARMONI Modular Intraocular Lens (IOL) System receives CE Mark for Europe

Tuesday, September 29, 2015

ClarVista Medical, Inc., a privately-held ophthalmic device company, announced today it received CE (Conformite Europeenne) Mark of the HARMONI Modular Intraocular Lens (IOL) System for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. The unique modular design is intended to enable safe and easy exchange of the optic component to reduce residual postoperative refractive error at the time of the primary surgery or at 3 months postoperatively.  In addition to CE Mark, ClarVista has also received ISO 13485 certification, an internationally recognized quality standard for medical devices.

"CE Mark approval and ISO 13485 certification are very important milestones for us and validate the dedication of the entire ClarVista team to deliver innovative products of the highest quality.  These milestones are an important part of achieving our vision of having the HARMONI Modular IOL system be the ophthalmologist's first choice for every cataract patient," said Paul McLean, CEO of ClarVista Medical.

Dr. Malik Kahook, Professor of Ophthalmology at the University of Colorado and co-inventor of the technology stated, "While these are noteworthy regulatory milestones achieved by ClarVista, this news is also of great significance for physicians and patients around the world who seek optimum vision after cataract extraction. Despite significant innovation in instruments that safely remove the cataract from the eye, the fundamental IOL design has not changed in more than five decades.  Today's IOLs are simply no longer able to meet the high expectations of patients and physicians.  There is significant unmet need for an advanced IOL system that can satisfy the visual needs of patients around the globe.  We designed this system to be easily and safely exchangeable without manipulation of the delicate capsular bag and this feature, by itself, will deliver great value to the market.  However, we think we can go well beyond that and have shown the promise to more accurately hit refractive targets after initial implantation of the HARMONI Modular IOL system. Early data also point towards significant reduction in the development of secondary cataracts (posterior capsular opacification), a common reason for deteriorating vision post-operatively. We are also working hard on adding further value to our platform technology. The HARMONI Modular IOL system really has the opportunity to disrupt the $3B global market for IOLs."